In yesterday’s Wall Street session, Alkermes plc (NASDAQ:ALKS) shares traded at $29.65, up 0.51% from the previous session.
ALKS stock price is now 2.88% away from the 50-day moving average and 11.15% away from the 200-day moving average. The market capitalization of the company currently stands at $4.80B.
With the price target enhanced from $25 to $36, Stifel Upgraded its rating from Hold to Buy for Alkermes plc (NASDAQ: ALKS). On June 17, 2024, TD Cowen recently initiated its ‘Buy’ rating on the stock quoting a target price of $34, while ‘Robert W. Baird’ rates the stock as ‘Outperform’
In other news, Hopkinson Craig C., EVP R&D, Chief Medical Officer sold 61,151 shares of the company’s stock on Dec 09 ’24. The stock was sold for $1,961,406 at an average price of $32.07. Upon completion of the transaction, the EVP R&D, Chief Medical Officer now directly owns 47,576 shares in the company, valued at $1.41 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Dec 09 ’24, Director LAURENCIN CATO T sold 2,691 shares of the business’s stock. A total of $85,708 was realized by selling the stock at an average price of $31.85. This leaves the insider owning 23,013 shares of the company worth $0.68 million. A total of 1.86% of the company’s stock is owned by insiders.
During the past 12 months, Alkermes plc has had a low of $22.90 and a high of $32.88. As of last week, the company has a debt-to-equity ratio of 0.28, a current ratio of 3.45, and a quick ratio of 3.03. According to the stock market information, the enterprise value for the company is $4264291584, which is based on a 15.10 price-to-earnings ratio, a 1.13 price-to-earnings-growth ratio, and a beta of 0.49. The fifty day moving average price for ALKS is $28.8084 and a two-hundred day moving average price translates $26.67075 for the stock.
The latest earnings results from Alkermes plc (NASDAQ: ALKS) was released for 2024-09-30. The net profit margin was 22.15% and return on equity was 29.23% for ALKS. The company reported revenue of $378.14 million for the quarter, compared to $380.94 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -0.73 percent. For the current quarter, analysts expect ALKS to generate $380.74M in revenue.
